CCL5/RANTES Antibody (676106)

CCL5/RANTES was detected in immersion fixed canine peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Canine CCL5/RANTES Monoclonal Antibody (Catalog # MAB60451) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

• Reactivity: Ca
• Applications: ICC/IF
• Clone: 676106
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

CCL5/RANTES Antibody (676106) Summary

• Immunogen: E. coli-derived recombinant canine CCL5/RANTES
  Ser24-Ser91
  Accession # Q8HYS0
• Specificity: Detects canine CCL5/RANTES in direct ELISAs. In Western blots, no cross-reactivity with recombinant CCL5/RANTES from cat, cotton rat, mouse, or human is observed. No cross-reactivity with recombinant mouse CCL7/MARC, rmCCL17/TARC, recombinant human (rh) CCL18/PARC, or rhCCL17/TARC is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CCL5
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL5/RANTES Antibody (676106)

• CCL5
• chemokine (C-C motif) ligand 5
• D17S136Enormally T-expressed, and presumably secreted
• EoCP
• Eosinophil chemotactic cytokine
• RANTES
• SISd
• SIS-delta
• small inducible cytokine A5 (RANTES)
• small inducible cytokine subfamily A (Cys-Cys), member 5
• Small-inducible cytokine A5
• T cell-specific protein P228
• T-cell specific protein p288
• TCP228T-cell-specific protein RANTES

Background

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature canine CCL5 shares 74%‑84% amino acid seqeuence identity with cotton rat, feline, human, mouse, and rat CCL5. CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (5, 6). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (7). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (8). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (9). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (10‑12). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (13‑15). CCL5 is up‑regulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (16).

1. Schall, T.J. et al. (1990) Nature 347:669.
2. Bacon, K.B. et al. (1995) Science 269:1727.
3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
5. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
6. Levy, J.A. (2009) J. Immunol. 182:3945.
7. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
8. DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
9. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
10. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
11. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
12. von Hundelshausen, P. et al. (2005) Blood 105:924.
13. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
14. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
15. Baltus, T. et al. (2003) Blood 102:1985.
16. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CCL5
• Uniprot:
  • Q8HYS0()